OdhiamboJAWilliamsHCClaytonTORobertsonCFAsherMI; ISAAC Phase Three Study Group. Global variations in prevalence of eczema symptoms in children from ISAAC Phase Three. J Allergy Clin Immunol2009;124(6):1251-8.e23.
3.
SilverbergJIHanifinJM. Adult eczema prevalence and associations with asthma and other health and demographic factors: a US population-based study. J Allergy Clin Immunol2013;132(5):1132-8.
4.
LeeJHSonSWChoSH. A comprehensive review of the treatment of atopic eczema. AllergyAsthma Immunol Res2016;8(3):181-90.
5.
HanifinJMReedML; Eczema Prevalence and Impact Working Group. A population-based survey of eczema prevalence in the United States. Dermat Contact Atopic Occup Drug2007;18(2):82-91.
6.
IlliSvon MutiusELauSet al. The natural course of atopic dermatitis from birth to age 7 years and the association with asthma. J Allergy Clin Immunol2004;113(5):925-31.
7.
GarmhausenDHagemannTBieberTet al. Characterization of different courses of atopic dermatitis in adolescent and adult patients. Allergy2013;68(4):498-506.
8.
EichenfieldLFTomWLBergerTGet al. Guidelines of care for the management of atopic dermatitis: section 2. Management and treatment of atopic dermatitis with topical therapies. J Am Acad Dermatol2014;71(1):116-32.
9.
SidburyRDavisDMCohenDEet al. Guidelines of care for the management of atopic dermatitis: section 3. Management and treatment with phototherapy and systemic agents. J Am Acad Dermatol2014;71(2):327-49.
10.
SidburyRTomWLBergmanJNet al. Guidelines of care for the management of atopic dermatitis part 4: prevention of disease flares and use of adjunctive therapies and approaches. J Am Acad Dermatol2014;71(6):1218-33.
11.
SaekiHNakaharaTTanakaAet al. Clinical practice guidelines for the management of atopic dermatitis 2016. J Dermatol2016;43(10):1117-45.
12.
LyndeCBarberKClaveauJet al. Canadian practical guide for the treatment and management of atopic dermatitis. J Cutan Med Surg2005;8(suppl 5):1-9.
13.
DruckerAMWangARLiW-QSevetsonEBlockJKQureshiAA. The burden of atopic dermatitis: summary of a report for the National Eczema Association. J Invest Dermatol2017;137(1):26–30.
14.
ZuberbierTOrlowSJPallerASet al. Patient perspectives on the management of atopic dermatitis. J Allergy Clin Immunol2006;118(1):226-32.
15.
ChamlinSLChrenM-M. Quality-of-life outcomes and measurement in childhood atopic dermatitis. Immunol Allergy Clin North Am2010;30(3):281-8.
16.
BickersDRLimHWMargolisDet al. The burden of skin diseases: 2004 a joint project of the American Academy of Dermatology Association and the Society for Investigative Dermatology. J Am Acad Dermatol2006;55(3):490-500.
17.
FilanovskyMGPootongkamSTamburroJESmithMCGanocySJNedorostST. The financial and emotional impact of atopic dermatitis on children and their families. J Pediatr2016;169:284-90.e5.
18.
EichenfieldLFTomWLChamlinSLet al. Guidelines of care for the management of atopic dermatitis: section 1. Diagnosis and assessment of atopic dermatitis. J Am Acad Dermatol2014;70(2):338-51.
19.
GiamYCHebertAADizonMVet al. A review on the role of moisturizers for atopic dermatitis. Asia Pac Allergy2016;6(2):120-8.
20.
EliasPMSteinhoffM. “Outside-to-inside” (and now back to “outside”) pathogenic mechanisms in atopic dermatitis. J Invest Dermatol2008;128(5):1067-70.
21.
EliasPMHatanoYWilliamsML. Basis for the barrier abnormality in atopic dermatitis: outside-inside-outside pathogenic mechanisms. J Allergy Clin Immunol2008;121(6):1337-43.
22.
Catherine MackCorrea MNebusJ. Management of patients with atopic dermatitis: the role of emollient therapy. Dermatol Res Pract2012;2012:e836931.
23.
ChiangCEichenfieldLF. Quantitative assessment of combination bathing and moisturizing regimens on skin hydration in atopic dermatitis. Pediatr Dermatol2009;26(3):273-8.
24.
SimpsonETrookmanNSRizerRLet al. Safety and tolerability of a body wash and moisturizer when applied to infants and toddlers with a history of atopic dermatitis: results from an open-label study. Pediatr Dermatol2012;29(5):590-7.
25.
LuckyAWLeachADLaskarzewskiPWenckH. Use of an emollient as a steroid-sparing agent in the treatment of mild to moderate atopic dermatitis in children. Pediatr Dermatol1997;14(4):321-4.
26.
NankervisHThomasKSDelamereFMBarbarotSRogersNKWilliamsHC. Scoping systematic review of treatments for eczema [Internet]. Southampton (UK): NIHR Journals Library; 2016 (Programme Grants for Applied Research). Available: http://www.ncbi.nlm.nih.gov/books/NBK363127/ (accessed Dec. 10, 2016).
27.
WirénKNohlgårdCNybergFet al. Treatment with a barrier-strengthening moisturizing cream delays relapse of atopic dermatitis: a prospective and randomized controlled clinical trial. J Eur Acad Dermatol Venereol2009;23(11):1267-72.
28.
CorkM. Optimising treatment of atopic dermatitis: the emollient to topical steroid prescribing ratio. Sci Insights Rep2003.
WilliamsHC. Established corticosteroid creams should be applied only once daily in patients with atopic eczema. BMJ2007;334(7606):1272.
31.
CallenJChamlinSEichenfieldLFet al. A systematic review of the safety of topical therapies for atopic dermatitis. Br J Dermatol2007;156(2):203-21.
32.
NielsenNVSørensenPN. Glaucoma induced by application of corticosteroids to the periorbital region. Arch Dermatol1978;114(6):953-4.
33.
Aubert-WastiauxHMoretLLe RhunAet al. Topical corticosteroid phobia in atopic dermatitis: a study of its nature, origins and frequency. Br J Dermatol2011;165(4):808-14.
34.
AshcroftDMDimmockPGarsideRSteinKWilliamsHC. Efficacy and tolerability of topical pimecrolimus and tacrolimus in the treatment of atopic dermatitis: meta-analysis of randomised controlled trials. BMJ2005;330(7490):516.
35.
LugerTBoguniewiczMCarrWet al. Pimecrolimus in atopic dermatitis: consensus on safety and the need to allow use in infants. Pediatr Allergy Immunol Off Publ Eur Soc Pediatr Allergy Immunol2015;26(4):306-15.
36.
PappKAWerfelTFölster-HolstRet al. Long-term control of atopic dermatitis with pimecrolimus cream 1% in infants and young children: a two-year study. J Am Acad Dermatol2005;52(2):240-6.
37.
HanifinJMPallerASEichenfieldLet al. Efficacy and safety of tacrolimus ointment treatment for up to 4 years in patients with atopic dermatitis. J Am Acad Dermatol2005;53(2 suppl 2):S186-94.
38.
HanifinJM. A reassuring rejoinder against malignant influences of topical calcineurin use in children. JAMA Dermatol2015;151(6):587-8.
39.
HanifinJGuptaAKRajagopalanR. Intermittent dosing of fluticasone propionate cream for reducing the risk of relapse in atopic dermatitis patients. Br J Dermatol2002;147(3):528-37.
40.
Berth-JonesJDamstraRJGolschSet al. Twice weekly fluticasone propionate added to emollient maintenance treatment to reduce risk of relapse in atopic dermatitis: randomised, double blind, parallel group study. BMJ2003;326(7403):1367.
41.
GlazenburgEJWolkerstorferAGerretsenALMulderPGHOranjeAP. Efficacy and safety of fluticasone propionate 0.005% ointment in the long-term maintenance treatment of children with atopic dermatitis: differences between boys and girls?Pediatr Allergy Immunol Off Publ Eur Soc Pediatr Allergy Immunol2009;20(1):59-66.
42.
PesericoAStädtlerGSebastianMFernandezRSVickKBieberT. Reduction of relapses of atopic dermatitis with methylprednisolone aceponate cream twice weekly in addition to maintenance treatment with emollient: a multicentre, randomized, double-blind, controlled study. Br J Dermatol2008;158(4):801-7.
43.
Van Der MeerJBGlazenburgEJMulderPGEgginkHFCoenraadsPJ. The management of moderate to severe atopic dermatitis in adults with topical fluticasone propionate. The Netherlands Adult Atopic Dermatitis Study Group. Br J Dermatol1999;140(6):1114-21.
44.
SchmittJvon KobyletzkiLSvenssonAApfelbacherC. Efficacy and tolerability of proactive treatment with topical corticosteroids and calcineurin inhibitors for atopic eczema: systematic review and meta-analysis of randomized controlled trials. Br J Dermatol2011;164(2):415-28.
45.
BrenemanDFleischerABAbramovitsWet al. Intermittent therapy for flare prevention and long-term disease control in stabilized atopic dermatitis: a randomized comparison of 3-times-weekly applications of tacrolimus ointment versus vehicle. J Am Acad Dermatol2008;58(6):990-9.
46.
WollenbergAReitamoSGirolomoniGet al. Proactive treatment of atopic dermatitis in adults with 0.1% tacrolimus ointment. Allergy2008;63(7):742-50.
47.
Suárez-FariñasMTintleSJShemerAet al. Nonlesional atopic dermatitis skin is characterized by broad terminal differentiation defects and variable immune abnormalities. J Allergy Clin Immunol2011;127(4):954-64.e1-4.
48.
RoekevischESpulsPIKuesterDLimpensJSchmittJ. Efficacy and safety of systemic treatments for moderate-to-severe atopic dermatitis: a systematic review. J Allergy Clin Immunol2014;133(2):429-38.
49.
SchmittJSchäkelKFölster-HolstR.et al. Prednisolone vs. ciclosporin for severe adult eczema: an investigator-initiated double-blind placebo-controlled multicentre trial. Br J Dermatol2010;162(3):661-8.
50.
CurtisJRWestfallAOAllisonJet al. Population-based assessment of adverse events associated with long-term glucocorticoid use. Arthritis Rheum2006;55(3):420-6.
51.
BolanosSHKhanDAHanczycM. Assessment of mood states in patients receiving long-term corticosteroid therapy and in controls with patient-rated and clinician-rated scales. Ann Allergy Asthma Immunol Off Publ Am Coll Allergy Asthma Immunol2004;92(5):500-5.
52.
SheaBSwindenMVGhogomuETet al. Folic acid and folinic acid for reducing side effects in patients receiving methotrexate for rheumatoid arthritis. J Rheumatol2014;41(6):1049-60.
53.
SilverbergJIGargNKPallerASFishbeinABZeePC. Sleep disturbances in adults with eczema are associated with impaired overall health: a US population-based study. J Invest Dermatol2015;135(1):56-66.
54.
KleinPAClarkRA. An evidence-based review of the efficacy of antihistamines in relieving pruritus in atopic dermatitis. Arch Dermatol1999;135(12):1522-5.
55.
LanganSMAbuabaraKHenricksonSEHoffstadOMargolisDJ. Increased risk of cutaneous and systemic infections in atopic dermatitis: a cohort study. J Invest Dermatol [Internet]. Feb. 12, 2017. Available: http://www.jidonline.org/article/S0022-202X(17)30175-6/abstract (accessed Apr. 5, 2017).
56.
WollenbergAZochCWetzelSPlewigGPrzybillaB. Predisposing factors and clinical features of eczema herpeticum: a retrospective analysis of 100 cases. J Am Acad Dermatol2003;49(2):198-205.
57.
HuangJTAbramsMTlouganBRademakerAPallerAS. Treatment of Staphylococcus aureus colonization in atopic dermatitis decreases disease severity. Pediatrics2009;123(5):e808-14.
58.
EichenfieldLFFriedlanderSFSimpsonELIrvineAD. Assessing the new and emerging treatments for atopic dermatitis. Semin Cutan Med Surg2016;35(5 suppl):S92-6.
59.
PallerASTomWLLebwohlMGet al. Efficacy and safety of crisaborole ointment, a novel, nonsteroidal phosphodiesterase 4 (PDE4) inhibitor for the topical treatment of atopic dermatitis (AD) in children and adults. J Am Acad Dermatol2016;75(3):494-503.e4.
60.
SimpsonELBieberTGuttman-YasskyEet al. Two phase 3 trials of dupilumab versus placebo in atopic dermatitis. N Engl J Med2017;376(1):1090.
61.
SimpsonEL. Atopic dermatitis: a review of topical treatment options. Curr Med Res Opin2010;26(3):633-40.
62.
EllisonJAPatelLRayDWDavidTJClaytonPE. Hypothalamic-pituitary-adrenal function and glucocorticoid sensitivity in atopic dermatitis. Pediatrics2000;105(4 pt 1):794-9.
63.
MargolisDJHoffstadOBilkerW. Lack of association between exposure to topical calcineurin inhibitors and skin cancer in adults. Dermatol Basel Switz2007;214(4):289-95.
64.
ArellanoFMWentworthCEAranaAFernándezCPaulCF. Risk of lymphoma following exposure to calcineurin inhibitors and topical steroids in patients with atopic dermatitis. J Invest Dermatol2007;127(4):808-16.
65.
TennisPGelfandJMRothmanKJ. Evaluation of cancer risk related to atopic dermatitis and use of topical calcineurin inhibitors. Br J Dermatol2011;165(3):465-73.
66.
HearnRMKerrACRahimKFFergusonJDaweRS. Incidence of skin cancers in 3867 patients treated with narrow-band ultraviolet B phototherapy. Br J Dermatol2008;159(4):931-5.
67.
ApfelbacherCJvan ZuurenEJFedorowiczZJupiterAMatterneUWeisshaarE. Oral H1 antihistamines as monotherapy for eczema. Cochrane Database Syst Rev2013;(2):CD007770.
LongCCFinlayAY. The finger-tip unit—a new practical measure. Clin Exp Dermatol1991;16(6):444-7.
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
